Gilteritinib, a second‐generation inhibitor, is the only US FDA‐approved FLT3 inhibitor to be used as a single agent for patients with relapsed or refractory AML having an FLT3 ITD, D835, or I836 mutation based on the results of the phase III ADMIRAL trial. Here, FLT3 is linked to acute myeloid leukemia.